{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04959903",
            "orgStudyIdInfo": {
                "id": "SI101-01"
            },
            "organization": {
                "fullName": "Smart Immune SAS",
                "class": "INDUSTRY"
            },
            "briefTitle": "Safety and Efficacy of SMART101 in Pediatric and Adult Patients With Hematological Malignancies After T Cell Depleted Allo-HSCT",
            "officialTitle": "A Phase I/II Study Evaluating the Safety and the Efficacy of SMART101 Injection to Accelerate Immune Reconstitution After T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric and Adult Patients With Hematological Malignancies",
            "therapeuticArea": [
                "Other"
            ],
            "study": "safety-and-efficacy-of-in-pediatric-and-adult-patients-with-hematological-malignancies-after-t-cell-depleted-allo-hsct"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-03",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-03-31",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-08",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2027-05",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2021-07-01",
            "studyFirstSubmitQcDate": "2021-07-12",
            "studyFirstPostDateStruct": {
                "date": "2021-07-13",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-03-02",
            "lastUpdatePostDateStruct": {
                "date": "2023-03-06",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Smart Immune SAS",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this study is to evaluate the safety and the efficacy of SMART101 (Human T Lymphoid Progenitor (HTLP)) injection to accelerate immune reconstitution after T cell depleted allogeneic hematopoietic stem cell transplantation (HSCT) in adult and pediatric patients with hematological malignancies."
        },
        "conditionsModule": {
            "conditions": [
                "Hematological Malignancies"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 36,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Adult patients affected by hematological malignancies",
                    "type": "EXPERIMENTAL",
                    "description": "Adult patients affected by acute leukemia (AML, ALL or acute leukemia of ambiguous lineage) or myelodysplastic syndrome eligible for a T depleted allogeneic HSCT",
                    "interventionNames": [
                        "Biological: Allogeneic T cell progenitors, cultured ex-vivo"
                    ]
                },
                {
                    "label": "Pediatric patients affected by hematological malignancies",
                    "type": "EXPERIMENTAL",
                    "description": "Pediatric patients affected by acute leukemia (AML, ALL or acute leukemia of ambiguous lineage) eligible for a T depleted allogeneic HSCT",
                    "interventionNames": [
                        "Biological: Allogeneic T cell progenitors, cultured ex-vivo"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "BIOLOGICAL",
                    "name": "Allogeneic T cell progenitors, cultured ex-vivo",
                    "description": "Injection of T cell progenitors at \\[Day 4-Day 10\\] after T cell depleted allogeneic HSCT",
                    "armGroupLabels": [
                        "Adult patients affected by hematological malignancies",
                        "Pediatric patients affected by hematological malignancies"
                    ],
                    "otherNames": [
                        "SMART101"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Cumulative incidence of grade III-IV GvHD",
                    "description": "to evaluate the safety profile of the study drug",
                    "timeFrame": "100 days post-HSCT"
                },
                {
                    "measure": "Occurrence of adverse events related to SMART101",
                    "description": "Number of adverse events and serious adverse events related to SMART101 tabulated for each dose and by age group to evaluate the safety profile of the study drug",
                    "timeFrame": "100 days post-HSCT"
                },
                {
                    "measure": "CD4+ T cell count",
                    "description": "to evaluate the efficacy of the study drug",
                    "timeFrame": "100 days post-HSCT"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "T cell immune reconstitution",
                    "description": "Time course of the T cell immune reconstitution, with a focus on naive CD4+ cells and total CD8+ cells",
                    "timeFrame": "up to Month 12 post-HSCT"
                },
                {
                    "measure": "Cumulative incidence of infections",
                    "timeFrame": "Day 90, and Months 6, 12 and 24 post-HSCT"
                },
                {
                    "measure": "Non-relapse mortality (NRM)",
                    "timeFrame": "Day 90, and Months 6, 12 and 24 post-HSCT"
                }
            ],
            "otherOutcomes": [
                {
                    "measure": "Overall Survival (OS)",
                    "timeFrame": "Month 24 post-HSCT"
                },
                {
                    "measure": "Disease-free Survival",
                    "timeFrame": "Month 24 post-HSCT"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\nGroup A (adults):\n\n1. Adult patients affected by:\n\n   * Acute leukemia (AML, ALL) defined as:\n\n     * Acute Myeloid Leukemia (AML):\n\n       * High risk AML in CR1; any adverse genetic abnormality, secondary or therapy related AML excluding good risk genetic abnormalities\n       * Chemo-refractory relapse (MRD+)\n       * \u2265 CR2\n     * Acute Lymphoblastic Leukemia (ALL):\n\n       * Chemo-refractory relapse (MRD+)\n       * High risk ALL in CR1; Philadelphia (like) or any poor risk feature\n       * \u2265 CR2\n     * Acute leukemia of ambiguous lineage:\n\n       * \u2265 CR1 with a minimal residual disease (MRD) \\<5% (flow cytometry, molecular and/or cytogenetics accepted)\n   * Myelodysplastic Syndrome (MDS) with least one of the following:\n\n     * Revised International Prognostic Scoring System risk score of intermediate or higher at the time of transplant evaluation.\n     * Life-threatening cytopenia.\n     * Karyotype or genomic changes that indicate high risk for progression to acute myelogenous leukemia, including abnormalities of chromosome 7 or 3, mutations of TP53, or complex or monosomal karyotype.\n     * Therapy related disease or disease evolving from other malignant processes.\n2. Patient eligible for a T-depleted allogeneic HSCT\n3. Age \u2265 18y and clinical condition compatible with allogeneic stem cell transplantation\n4. Karnofsky index \u2265 70% prior to conditioning regimen\n5. Patients with normal organ function prior to conditioning regimen\n\nGroup B (pediatrics):\n\n1. Pediatric patients affected by acute leukemia defined as:\n\n   * Acute Myeloid Leukemia (AML):\n\n     * High risk AML in CR1; any adverse genetic abnormality, secondary or therapy related AML excluding good risk genetic abnormalities,\n     * Chemo-refractory relapse (MRD+)\n     * \u2265 CR2\n   * Acute Lymphoblastic Leukemia (ALL):\n\n     * Chemo-refractory relapse (MRD+)\n     * High risk ALL in CR1; Philadelphia (like) or any poor risk feature\n     * \u2265 CR2\n   * Acute leukemia of ambiguous lineage:\n\n     * \u2265 CR1 with a minimal residual disease (MRD) \\<5% (flow cytometry, molecular and/or cytogenetics accepted)\n2. Patient eligible for a T-depleted allogeneic HSCT\n3. Age \\< 18y at the time of inclusion\n4. Absence of a matched sibling donor (MSD)\n5. Lansky \u2265 70% / Karnofsky performance status \u2265 70% prior to conditioning regimen\n6. Patients with normal organ function prior to conditioning regimen\n\nExclusion Criteria:\n\nGroups A and B:\n\n1. Use of an HLA matched Cord Blood (8/8 allele matched) or haploidentical donor\n2. Prior therapy with allogeneic stem cell transplantation\n3. Treatment with another cellular therapy within one month before inclusion",
            "healthyVolunteers": false,
            "sex": "ALL",
            "stdAges": [
                "CHILD",
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Fr\u00e9d\u00e9ric LEHMANN, MD",
                    "role": "CONTACT",
                    "phone": "+32 (0) 492 46 23 55",
                    "email": "frederic.lehmann@smart-immune.com"
                },
                {
                    "name": "Laura SIMONS, MD, PhD",
                    "role": "CONTACT",
                    "email": "laura.simons@smart-immune.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Jaap-Jan BOELENS, MD, PhD",
                    "affiliation": "Memorial Sloan Kettering Cancer Center (MSKCC)",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Memorial Sloan Kettering Cancer Center (MSKCC)",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10065",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Jaap-Jan BOELENS, MD, PhD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        },
                        {
                            "name": "Miguel-Angel PERALES, MD",
                            "role": "SUB_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000019337",
                    "term": "Hematologic Neoplasms"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000006402",
                    "term": "Hematologic Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M21314",
                    "name": "Hematologic Neoplasms",
                    "asFound": "Hematological Malignancies",
                    "relevance": "HIGH"
                },
                {
                    "id": "M9490",
                    "name": "Hematologic Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC15",
                    "name": "Blood and Lymph Conditions"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        }
    },
    "hasResults": false
}